Crude incidences of recurrent VTE and major bleeding according to individual minor persistent or transient risk factors
| . | Recurrent VTE, n (%) . | |
|---|---|---|
| Risk factor . | Rivaroxaban 10 and 20 mg . | Placebo/aspirin . |
| Provoked by minor persistent risk factors, n (%) | ||
| Inflammatory bowel disease | 0/26 (0.0) | 0/14 (0.0) |
| Lower extremity paralysis or paresis | 0/12 (0.0) | 0/4 (0.0) |
| Congestive heart failure | 2/23 (8.7) | 0/10 (0.0) |
| Body mass index >30 kg/m2 | 13/907 (1.4) | 25/536 (4.7) |
| Creatinine clearance <50 mL/min | 2/122 (1.6) | 8/104 (7.7) |
| Family history of VTE | 2/31 (6.5) | 0/13 (0.0) |
| Hereditary thrombophilia | 3/173 (1.7) | 8/102 (7.8) |
| Acquired thrombophilia | 1/20 (5.0) | 0/5 (0.0) |
| Provoked by minor transient risk factors, n (%) | ||
| Immobilization | 1/99 (1.0) | 5/68 (7.4) |
| Travel >8 h | 0/11 (0.0) | 0/9 (0.0) |
| Use of estrogen therapy | 0/75 (0.0) | 1/64 (1.6) |
| Pregnancy or puerperium | 0/17 (0.0) | 0/2 (0.0) |
| Leg injury with impaired mobility | 0/76 (0.0) | 2/40 (5.0) |
| . | Recurrent VTE, n (%) . | |
|---|---|---|
| Risk factor . | Rivaroxaban 10 and 20 mg . | Placebo/aspirin . |
| Provoked by minor persistent risk factors, n (%) | ||
| Inflammatory bowel disease | 0/26 (0.0) | 0/14 (0.0) |
| Lower extremity paralysis or paresis | 0/12 (0.0) | 0/4 (0.0) |
| Congestive heart failure | 2/23 (8.7) | 0/10 (0.0) |
| Body mass index >30 kg/m2 | 13/907 (1.4) | 25/536 (4.7) |
| Creatinine clearance <50 mL/min | 2/122 (1.6) | 8/104 (7.7) |
| Family history of VTE | 2/31 (6.5) | 0/13 (0.0) |
| Hereditary thrombophilia | 3/173 (1.7) | 8/102 (7.8) |
| Acquired thrombophilia | 1/20 (5.0) | 0/5 (0.0) |
| Provoked by minor transient risk factors, n (%) | ||
| Immobilization | 1/99 (1.0) | 5/68 (7.4) |
| Travel >8 h | 0/11 (0.0) | 0/9 (0.0) |
| Use of estrogen therapy | 0/75 (0.0) | 1/64 (1.6) |
| Pregnancy or puerperium | 0/17 (0.0) | 0/2 (0.0) |
| Leg injury with impaired mobility | 0/76 (0.0) | 2/40 (5.0) |
Minor persistent risk factors are listed for the patient who did not have a major persistent risk factor; minor transient risk factors are listed for patients who did not have persistent risk factors. Hereditary thrombophilia includes deficiency of antithrombin, protein C, or protein S, and factor V Leiden or the prothrombin gene mutation. Acquired thrombophilia includes antiphospholipid syndrome. A patient can contribute to multiple rows.